Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, non prostate

1701 - Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): results of a GETUG multicenter phase II trial (Axipap)


20 Oct 2018


Poster Discussion session - Genitourinary tumours, non prostate


Cytotoxic Therapy;  Clinical Research

Tumour Site

Renal Cell Cancer


Sylvie Negrier


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


S. Negrier1, N. Rioux-Leclercq2, A. Ravaud3, G. Gravis4, L. Geoffrois5, C.M. Chevreau6, F. Rolland7, E. Blanc8, C. Segura-Ferlay9, D. Perol10, M. Gross Goupil3, S. Dermeche4, A. Flechon1, L. Albiges11, B. Escudier12

Author affiliations

  • 1 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Medical Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 4 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 5 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 6 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 7 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 8 Clinical research Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 9 Biostatistics, Centre Leon Bérard, Lyon/FR
  • 10 Clinical research, Centre Léon Bérard, 69008 - Lyon/FR
  • 11 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 12 Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1701


PRC represents 10-15% of renal carcinomas; there is no standard treatment at the metastatic stage. Few trials were conducted with sunitinib, everolimus and more recently savolitinib, with disappointing response rates. Axitinib, an inhibitor of VEGF receptors, indicated as 2d line treatment in advanced renal cell carcinoma was investigated.


Axipap is a French multicentre phase II study. A central pathology review was required before inclusion. Other criteria were adult patients (pts) with measurable disease, ECOG PS 0 or 1, no previous treatment, no brain metastases and adequate organ functions. Axitinib was started at 5 mg twice a day orally with dose adaptations according to the recommendations. Primary endpoint was the progression free rate (PFR) at 24 weeks. A minimum of 42 evaluable pts were required to show that 45% (one sided 95% lower limit) pts did not progress at 24 weeks.


55 pts were screened, papillary was not confirmed in 5 (9.1%), 6 (10.9%) had other exclusion criteria. 44 pts, 12 and 30 papillary type 1 and 2, respectively, 1 mixed and 1 undetermined were enrolled. Median age was 65 (27-82), 84% pts were males, 23.8% were in the good, 45.2% in the intermediate and 31% pts in the poor IMDC prognostic groups. The median follow up time is 13.9 months (0.5-21), 5 pts did not yet reach 24 weeks. PFR at 24 weeks is 47.4% (95%CI 34.0-/), 50% (95%CI 24-/) and 46.4% (95%CI 30.9-/) in type 1 and 2 respectively; best response rate is 26.8% (11/41) with 1 PR and 10 PR in type 1 and 2 respectively, median response duration is 24.4 weeks (15-55). Median PFS is 24.7 weeks (95%CI 21-38). At the time of this analysis, 16 pts (36.4%) have died. Treatment related all grade toxicity was as expected with fatigue 73%, hypertension 61%, dysphonia 55%, diarrhea 52%, loss of appetite 30%, hand-foot syndrome 23%; grade 3-4 events were hypertension 25%, digestive symptoms 9% and PS decrease 5%.


This first trial of axitinib in mPRC shows encouraging efficacy, especially in type 2 PRC. Toxicity was manageable. Axitinib appears as a good candidate to combine with immunotherapy for future trials in mPRC. Expert pathology review should be recommended in this setting.

Clinical trial identification

EudraCT: 2014-005426-36.

Legal entity responsible for the study

Centre Leon Bérard, Lyon, France.



Editorial Acknowledgement


S. Negrier: Honoraria: Pfizer, BMS, Ipsen, Eusapharma, Novartis; Research grant: Pfizer; Travels: Pfizer, BMS, Ipsen. N. Rioux-Leclercq: Honoraria: Pfizer, Ipsen. A. Ravaud: Honoraria: Pfizer, Novartis, BMS, Roche, Ipsen; Meeting accommodations: Pfizer, Novartis, BMS, Roche, Ipsen. G. Gravis: Travel funding: Pfizer, BMS. L. Geoffrois: Honoraria: Ipsen, BMS, Novartis; Travels: Ipsen, Jansen, BMS, MSD, Merck. C.M. Chevreau, F. Rolland: Honoraria: Novartis, Pfizer, BMS, Ipsen. D. Perol: Honoraria: AstraZeneca, Roche, Janssen, Ipsen. M. Gross Goupil: Honoraria: Pfizer, Ipsen, Novartis, BMS, Roche. A. Flechon: Honoraria: Pfizer, Novartis, Astellas, Sanofi, Janssen, Roche, BMS, MSD. L. Albiges: Consulting: BMS, Novartis; Grant funding: Amgen, Pfizer, BMS, Ipsen, Novartis, Roche, Astellas. B. Escudier: Honoraria: Pfizer, Novartis, BMS, Roche, Ipsen, EUSA Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.